Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOXSIALO-TRIAL
2024-512160-58-00Phase 4Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in cerebral palsy (CP) and hypersalivation comparing Botulinum toxin A arm with Scopolamine patch arm (2 arms). Primary endpoint: Primary endpoint - change in DIS score at 15 months. Started Jul 2024; status: completed.
02
Drugs
botulinum toxin type Ascopolamine
03
Conditions
cerebral palsy (CP)hypersalivation
Beyond the preview
Go deeper on 2024-512160-58-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512160-58-00.